Who is sponsoring NCT05849740?

NCT05849740 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT05849740?

Interventions in NCT05849740: Daratumumab and corticosteroid treatment.

What condition does NCT05849740 study?

NCT05849740 studies Acquired Hemophilia.

Is NCT05849740 still recruiting?

NCT05849740 is currently recruiting now. Last updated 5 August 2025.

Last reviewed 2025-08-05 · How we verify

NCT05849740: AHA2023

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A

Recruiting now Phase 4 Last updated 5 August 2025

What this trial tests

Phase 4 trial testing Daratumumab and corticosteroid treatment in Acquired Hemophilia in 25 participants. Currently enrolling.

Timeline

22 May 2023

Primary endpoint
30 April 2027

31 October 2027

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	22 May 2023
Primary completion	30 April 2027
Estimated completion	31 October 2027
Sites	1 location across China

Drugs / interventions tested

Daratumumab and corticosteroid treatment — full drug profile →

Conditions studied

Acquired Hemophilia — all drugs for Acquired Hemophilia →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

18 and older, any sex, with Acquired Hemophilia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the time of response, sustained remission rate and relapse rate of CD38 monoclonal antibody (Daratumumab) combined corticosteroid in the treatment of AHA. To evaluate the safety of CD38 monoclonal antibody in the treatment of AHA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05849740 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 5 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05849740.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing